Circulating cell-free mRNA (cfmRNA) is a powerful tool in cancer diagnostics that can be measured quantitatively to assess the presence or absence of molecular residual disease (MRD) in a patient’s blood. OncoDxRx, an industry leader in cfmRNA technology, was the pioneer and inventor of cfmRNA-informed MRD testing, launching OncoMRD in 2024, which has now been validated in patients across lung and breast cancers.

Because it is highly sensitive, OncoMRD can detect very small traces of tumor activity (beyond tumor mutations) in the blood so clinicians can detect earlier if cancer may be present to inform a patient’s treatment and surveillance strategy.

As a custom-built assay based on the unique gene signature of each patient’s tumor, OncoMRD identifies and tracks tumor activity beyond tumor itself, including signals from non-tumor TME and immune cells. A patient’s blood can be used to monitor for the presence or absence of the disease over time.

OncoMRD has potential clinical utility across lung and breast cancers to help answer important clinical questions along the entire continuum of care including:

• In the neoadjuvant setting to assess response to neoadjuvant therapy and to help inform next steps
• In the adjuvant setting, it can be used to stratify high-risk patients, evaluate the need for adjuvant chemotherapy, and inform when to escalate or right-size treatment
• In the surveillance setting, OncoMRD can be used serially to detect MRD with greater sensitivity than current standard of care ctDNA tools
• Monitoring treatment response in patients on immune checkpoint inhibitors (ICIs) to identify pseudo progression or clarify indeterminate findings.

OncoMRD has been in the validation phase for monitoring disease progression, recurrence, or relapse for patients with breast cancer and lung cancer, in the adjuvant and surveillance settings.